Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).

The oncologist - 3 May 2024

Sahu Kamal Kant, Li Haoran, Mathew Thomas Vinay, Benson Mallory, Boucher Ken, Gupta Sumati, Kohli Manish, Swami Umang, Agarwal Neeraj, Maughan Benjamin L

Abstract excerpt

BACKGROUND: Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Germ-Line Mutation

Share to Indoles

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38452035
DOI: 10.1093/oncolo/oyae030
PMCID: PMC11067793

Genes

ATM
BRCA1
RAD51
BCR
BRCA2
BRIP1
CHEK2
PALB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).PMID 38452035Read ↗

BRCA Mutations in Prostate Cancer: Prognostic and Predictive ImplicationsSemantic proximity Read ↗

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsSemantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

BRCAness and prostate cancer: diagnostic and therapeutic considerations.Semantic proximity Read ↗

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the ClinicSemantic proximity Read ↗

Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

PARP Inhibitors in Prostate Cancer.Semantic proximity Read ↗

Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer.Semantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.